PQR620 is a potent and selective inhibitor of mTORC1/2 mTOR-containing complexes that was developed by PIQUR Therapeutics [2
]. It is brain-penetrating and is being analysed for clinical potential in neurological disorders and cancer. PQR620 was designed as a more effective alternative to the rapalogs sirolimus
which show only modest overall response rates in solid tumours [1
]. Chemically PQR620 is a rationally designed derivative of bimiralisib
(PQR309), in which bimiralisib's trifluoromethyl group is substituted by a difluoromethyl group, and its morpholino groups are substituted with oxo-azabicyclo moieties.